Scientific publications
We list below some of the key scientific publications for the three drugs that BioAxone has developed.
NOTE: The links provided below redirect to third-party websites that may require a subscription to access publications.
Cerebral Cavernous Malformationg and Stroke
A brain-targeted orally available ROCK2 inhibitor benefits mild and agressive cavernous angioma disease. 2020. McKerracher, L, Shenkar,R., Abbinanti, M, Cao, Y., Peiper, A., Liao, JK., Lighte, R., Moore, T., Hobson,N., Gallione,C., Ruschel,J., Koskimaki, J., Girard, R., Rosen, K., Marchuk, D.A., Awad, I.A. Cerebral Blood Flow and Metabolism 44(11):1238-1252
The novel ROCK2 selective inhibitor NRL-1049 preserves the blood brain barrier after acute injury. 2024. Mulder, IA., Abbinanti, M., Woller, SA., Ruschel, J., Coutinho, J., deVries, HE, vanBavel, E., Rosen, K., McKerracher, L., Ayata, C. J. Cerebral Blood Flow and Metabolism 44(11):1238-1252.
BA-210 and Spinal Cord Injury
A randomized controlled trial of local delivery of a rho inhibitor (VX-210) in patients with acute traumatic cervical spinal cord injury. 2021. Fehlings, M. Chen, Y, Aarabi, Ahmad, F.Anderson, K.D., Dumont, T., Fourney, D.R., Harrop, J.S., Kim, K.D., Kwon, B., Lingam, H.K., Rizzo, M., Shih, L.C., Tsai, E.C. Vaccaro, A., McKerracher, L. J. Neurotrauma 38(15):2065.
Rho inhibitor VX-210 in acute traumatic subaxial cervical spinal cord injury: Design of the Spinal Cord Injury Rho Inhibition InvestiGation (SPRING) Trial. Fehlings, Kim, Aarabi, Rizzo, Bond, McKerracher, Vaccaro, Okonkwo 2018. 2018. Des Journal of Neurotrauma. 35:1-8
A phase I/IIa clinical trial to assess the safety, feasibility, and preliminary efficacy of a recombinant Rho protein antagonist in patients with severe cervical or thoracic spinal cord injury.2011. Fehlings, M.G., Theodore, N., Maurais, G., Kuntz, C., Shaffrey, C.I., Kwon, B.K., Chapman, A., Yee, A., Tighe, A.. Haynes,B., McKerracher, L. J. Neurotrauma 28:787-796
Analysis of recruitment and outcomes in the Phase I/Iia Cethrin clinical trial for acute spinal cord injury. 2013. Mckerracher, L., Anderson, K., Journal of Neurotrauma 30: 1795-1804
Local Inhibition of Rho signaling by cell permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury, 2008. Lord-Fountain,S., Yang,F., Diep,Q., Dergham,P., Munzer,S, Tremblay, P. McKerracher,L.J. Neurotrauma 25:1309-1322.
Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. 2003. Dubreuil, CI., Winton, MJ., McKerracher, LJ. Cell Biol. 163 (2):233
BA-210 and Traumatic Brain Injury
Activation of Rho after traumatic brain injury in rats. 2005. Dubreuil, C., Markland, N., McIntosh, T.K., McKerracher, L. Journal of Neurotrauma 23:309
Self-delivering RNAi to silence PTEN
Self-delivering RNAi compounds as therapeutic agents in the central nervous system to enhance axonal regeneration after injury. 2022. Woller, SA, Ruschel, J., Morquette, B., Cardia, J. Yan, D., Holton, K., Shmushkovich, T., Niederst, E., Bulock, K., Wolfson, A, Abbinanti, A., Fournier, A, McKerracher, L., Rosen, K. iScience 25(6) 104379